Fapon Showcases Integrated IVD Solutions at Medlab Middle East 2025 “`

6e49bfd61235ce8d6b9dc15bf6022185 Fapon at Medlab Middle East 2025: Advancing Local Diagnostic Industry through One-stop IVD Solutions

DUBAI, UAE, February 3, 2025 — At Medlab Middle East 2025 in Dubai, UAE, from February 3 to 6, global life sciences leader Fapon is showcasing its comprehensive, integrated IVD solutions and sharing insights with international partners. Fapon is highlighting its technology transfer and local manufacturing services to support the growth of the regional IVD industry.

Fapon’s exhibition features IVD solutions using various technologies, including chemiluminescence immunoassay (CLIA), biochemistry, next-generation sequencing (NGS), polymerase chain reaction (PCR), lateral flow assay (LFA), and fluorescence immunoassay (FIA), for clinical labs and point-of-care testing (POCT). Fapon’s integrated approach combines open-system instruments, reagent services, and raw materials to offer reliable, adaptable, and streamlined services, particularly beneficial for local IVD companies developing or expanding their production. This ultimately improves care for local patients. Fapon aims to accelerate product development and market entry for global IVD manufacturers through technology transfer and local production.

Fapon’s CLIA and biochemistry offerings exemplify its integrated approach. Its CLIA solution includes the Shine i-series open-system CLIA analyzers and over 80 reagent services (e.g., vitamin D, NT-proBNP, hs-cTnI, and PCT assays) and core raw materials. Fapon provides comprehensive CLIA products and services, from development and registration to quality management system (QMS) setup and after-sales support. Its biochemistry solution offers matching antibodies, antigens, latex particles, coupling procedures, and analyzers, helping partners rapidly develop IVD tests. These solutions showcase Fapon’s commitment to advanced diagnostic technologies and customized services meeting the localization needs of IVD manufacturers. Fapon’s PCR solution offers POCT instruments with 30-minute results and customized reagents, while its FIA solution provides multiple analyzers and reagents for over 40 diseases.

With over two decades of experience supplying high-quality IVD raw materials, Fapon is a leading global supplier to major IVD manufacturers. Its advanced technology platforms for antibody production include phage display and single B cell technologies. Fapon addresses diagnostic needs across various diseases, including respiratory, infectious, tropical diseases, and Alzheimer’s disease.

Fapon’s extensive network includes over 100,000 m² of high-standard facilities and five global R&D centers (Boston and San Francisco in the United States; Dongguan, Shenzhen, and Shanghai in China), enabling the consistent development and delivery of cutting-edge products and services. Fapon plans to strengthen partnerships in emerging markets, enhancing healthcare services regionally.

About Fapon

Fapon is a leading global life sciences company providing integrated solutions and services for diagnostics, biopharmaceuticals, and biotherapy. Integrating total IVD solutions – innovative open instrument platforms, reagent services, and core IVD raw materials – Fapon is a leading supplier in in-vitro diagnostics. Fapon also offers advanced therapeutic technologies and AI algorithm platforms that contribute to better global health. With a strong global R&D, manufacturing, sales, and service network, Fapon’s products are present in 68 countries and regions, serving over 2,500 business partners.

Logo –

“`

elong